PF-06821497

Phase 3Small molecule

PF-06821497 is one of 21 small molecule programs targeting Metastatic Castration-Resistant Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Castration-Resistant Prostate CancerRecruiting

Metastatic Castrate Resistant Prostate Cancer (mcrpc)Active, not recruiting

Metastatic Castration-Resistant Prostate CancerPhase 3

Recruiting

Metastatic Castrate Resistant Prostate Cancer (mcrpc)Phase 3

Active, not recruiting

Competition

Competitive Landscape

27 competitors in Metastatic Castration-Resistant Prostate Cancer

#DrugCompanyPhaseTrials

Xtandi

Astellas

Approved

11 2

Zytiga

Johnson & Johnson

Phase 3

10 3

Lynparza

AstraZeneca

Phase 3

4 4

Nubeqa

Bayer

Phase 3

4 5

Taxotere

AAvyxa

Phase 3

7 6

Fotivda

Roche

Phase 2

1 7

Velcade

SShilpa Grover, MD, MPH

Phase 2

1 8

Zanzalintinib

Merck & Co.

Phase 2

1 9

XL092

Roche

Phase 2

1 10

Cabometyx

Bristol-Myers Squibb

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Active, not recruiting

Metastatic Castrate Resistant Prostate Cancer (mcrpc)

NCT06551324

Phase 3Recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT06629779

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia1 trial

A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.

Completed· Pfizer logo

Pfizer·Phase 1·NCT06392230·6 enrolled

Adult1 trial

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

Completed· Pfizer logo

Pfizer·Phase 1·NCT05767905·18 enrolled

Metastatic Castration-Resistant Prostate Cancer1 trial

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT06629779·900 enrolled

Metastatic Castrate Resistant Prostate Cancer (mCRPC)1 trial

A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT06551324·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for PF-06821497. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PF-06821497 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PF-06821497. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

PF-06821497

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Acute Lymphoblastic Leukemia1 trial

Adult1 trial

Metastatic Castration-Resistant Prostate Cancer1 trial

Metastatic Castrate Resistant Prostate Cancer (mCRPC)1 trial

References

Drug Info

Quick Facts

Related News